

STROBE Statement - Checklist for cohort studies

Manuscript: Hemoglobin-to-Red Blood Cell Distribution Width Ratio and Mortality
among U.S. Adults with Diabetes or Prediabetes: A Nationwide Population-Based Cohort Study

Topic	Item No.	Recommendation	Page No.
Title and abstract	1(a)	Indicate the study's design with a commonly used term in the title or the abstract	1, 3
	1(b)	Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6-7
Methods			
Study design	4	Present key elements of study design early in the paper	3, 8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-9
Participants	6(a)	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	8-9, 12
	6(b)	For matched studies, give matching criteria and number of exposed and unexposed	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources / measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-9
Bias	9	Describe any efforts to address potential sources of bias	10-11, 19
Study size	10	Explain how the study size was arrived at	12, 28
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-10
Statistical methods	12(a)	Describe all statistical methods, including those used to control for confounding	10-11
	12(b)	Describe any methods used to examine subgroups and interactions	10-11
	12(c)	Explain how missing data were addressed	12, 28
	12(d)	If applicable, explain how loss to follow-up was addressed	Not applicable
	12(e)	Describe any sensitivity analyses	11
Results			
Participants	13(a)*	Report numbers of individuals at each stage of study - e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12, 28
	13(b)	Give reasons for non-participation at each stage	12, 28
	13(c)	Consider use of a flow diagram	28
Descriptive data	14(a)*	Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	12, 26
	14(b)	Indicate number of participants with missing data for each variable of interest	12, 28
	14(c)	Summarise follow-up time (e.g., average and total amount)	2-3
Outcome data	15*	Report numbers of outcome events or summary measures over time	3, 27
Main results	16(a)	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10, 13, 27
	16(b)	Report category boundaries when continuous variables were categorized	8-10
	16(c)	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable

STROBE Statement - Cohort Studies Checklist (continued)

Topic	Item No.	Recommendation	Page No.
Other analyses			
Other analyses	17	Report other analyses done - e.g., analyses of subgroups and interactions, and sensitivity analyses	14-15, 30
Discussion			
Key results	18	Summarise key results with reference to study objectives	16, 20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-20
Generalisability	21	Discuss the generalisability (external validity) of the study results	8, 19
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

* Give information separately for exposed and unexposed groups, where applicable.

Reporting locations refer to the page numbers of the supplied 30-page manuscript.

Based on the STROBE Statement Checklist for Cohort Studies (www.strobe-statement.org).